Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) [clinicaltrials:NCT00517491]

Bio2RDF identifier

NCT00517491

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00517491

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00517491

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

10

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00517491 arm group c4ca4238a0b923820dcc509a6f75849b [clinicaltrials_resource:NCT00517491/arm-group/c4ca4238a0b923820dcc509a6f75849b]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:e1cc824d280c91ae87f42b833a1f7389

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of the prot ...... tide Autogel (Somatuline ATG)

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Study to Evaluate Patients Wit ...... otide Autogel (Somatuline ATG)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:3c91a4bbf112a1b92513dbbc196220a9]

GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:46855054beea2697a41ad9c5095b9c16]

GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:70c6257b2167adcb8c95da247fbdcb5d]

GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:eb9c17c4f7cc152b1219d5f12c0cd5c6]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:3d1f6bd26b1a02b4f5206a3a550a4562]

GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:ca4f763b717ebbc3ec49eb1ca2292685]

GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:ca9da0264a324cbe48dd805b3aa5fe68]

completion date [clinicaltrials_vocabulary:completion-date]

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00517491 [clinicaltrials_resource:1d68006b5a3698dbc7035777575d256d]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2007-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

lanreotide (Autogel formulation) [clinicaltrials_resource:e1801d801d6352a449f150ef2d597952]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Lanreotide [clinicaltrials_resource:05feb48e6eb643d3fbbedf29fbc8a04e]

Angiopeptin [clinicaltrials_resource:b5a22ed6a8d78563379b89fd804db18f]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2008-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

location [clinicaltrials_vocabulary:location]

Centro Médico Nacional Siglo XXI, IMSS [clinicaltrials_resource:ee391038a2ce04e08d1a2a58609545a5]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00517491

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Pilot Study to Evaluate the ...... otide Autogel (Somatuline ATG)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

A-38-52030-725

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Marcus V. Chio Ming Coelho de Sa, MD [clinicaltrials_resource:4cd05139d5b6fc24aa90bae7922d262d]

overall status [clinicaltrials_vocabulary:overall-status]

Withdrawn [clinicaltrials_resource:f62dedad685b570f499b61e94084dab2]

oversight [clinicaltrials_vocabulary:oversight]

Mexico: Federal Commission for Protection Against Health Risks [clinicaltrials_resource:aafab05fd261641608ae8db8c37ee41d]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

source [clinicaltrials_vocabulary:source]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

start date [clinicaltrials_vocabulary:start-date]

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00517491 study design [clinicaltrials_resource:442fc75515cf76e693f6dc2798fe9d99]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00517491

verification date [clinicaltrials_vocabulary:verification-date]

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

why stopped [clinicaltrials_vocabulary:why-stopped]

Administrative reasons

http://www.w3.org/2001/XMLSchema#string

identifier

clinicaltrials:NCT00517491

http://www.w3.org/2001/XMLSchema#string

title

Study to Evaluate Patients Wit ...... otide Autogel (Somatuline ATG)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Study to Evaluate Patients Wit ...... ) [clinicaltrials:NCT00517491]

@en